MedMira Inc. (TSX Venture: MIR, NSDQ: MMIRF), a Canadian company, received a China patent for its rapid diagnostic device and assay (Chinese Patent Application No. 02819646.5). The patents covers the rapid flow-through technology (RFT) platform on which the company has built its line of 3-minute tests for HIV, hepatitis and other diseases.

Previously, MedMira was granted patents for the technology in the US and Europe. With the third approval in hand, MedMira said it has won the “triple crown.”

In the first nine months of fiscal 2008, MedMira reported revenues of $1.3 million, which were lower than the $1.7 million the company recorded in the similar 2007 period.

MedMira says it is continuing to seek partners to further its growth as a company. These initiatives include seeking companies who want to build new rapid tests on MedMira’s RFT platform.

MedMira is an approved supplier to US Agency for International Development (USAID) and the Pan American Health Organization (PAHO).